XML 32 R21.htm IDEA: XBRL DOCUMENT v3.25.3
SHAREHOLDERS’ EQUITY
 9 Months Ended
Sep. 30, 2025
Equity [Abstract]  
SHAREHOLDERS’ EQUITY

NOTE 11 – SHAREHOLDERS’ EQUITY

 

Common Stock

 

At the Company’s Annual Meeting of Shareholders held in July 2020, the Company approved the Restated 2014 Omnibus Long Term Incentive Plan (the “2014 LTIP”) in which the Company’s directors, officers, employees and consultants are eligible to participate. The 2014 LTIP terminated on September 3, 2024, and no future awards may be granted pursuant to the 2014 LTIP. Previously granted awards under the 2014 LTIP will remain outstanding until they expire by their terms or under the terms of the 2014 LTIP.

 

On June 12, 2024, the Company’s shareholders approved the 2024 Omnibus Long-Term Incentive Plan (the “2024 LTIP”), which went into effect upon shareholder approval. The maximum number of shares of the Company’s common stock that may be delivered pursuant to awards granted under the 2024 LTIP is 1,000,000, subject to increase by any awards under the 2014 LTIP (i) that were outstanding on or after June 12, 2024, and that, on or after such date, are forfeited, expire or are canceled, and (ii) any shares subject to awards relating to common stock under the 2014 LTIP that are settled in cash on or after June 12, 2024 (the “Prior LTIP Awards”). The 2024 LTIP also provides that, to the extent an award under the 2024 LTIP or a Prior LTIP Award is forfeited, expires or is canceled, in whole or in part, the shares subject to such forfeited, expired or canceled award may again be awarded under the 2024 LTIP. As of September 30, 2025, a total of 200,304 shares, net of forfeitures, had been issued under the 2024 LTIP and 799,833 were available for issuance under the 2024 LTIP.

 

 

Restricted Stock Awards

 

During the nine months ended September 30, 2025, the Company issued restricted stock awards under the 2024 LTIP which are subject to certain vesting provisions and other terms and conditions set forth in each recipient’s respective restricted stock agreement. The Company issued 200,304 shares, net of forfeitures, under the 2024 LTIP, of restricted common stock to employees, directors, and certain advisors of the Company during the nine months ended September 30, 2025. The fair value of these awards was $6,829,868 based on the closing price of the Company’s common stock on the respective grant dates, which will be recognized as compensation expense on a straight-line basis over the vesting period of the awards.

 

Share-based compensation expense of $1,232,445 and $1,025,431 was recognized in “Operating expenses” in the accompanying Consolidated Statements of Operations during the three months ended September 30, 2025 and 2024, respectively. Share-based compensation expense of $3,972,788 and $3,240,362 was recognized in “Operating expenses” in the accompanying Consolidated Statements of Operations during the nine months ended September 30, 2025 and 2024, respectively.

 

At September 30, 2025, there was $7,034,070 of total unrecognized share-based compensation expense related to unvested share-based equity awards. Unrecognized share-based compensation expense is expected to be recognized over a weighted-average period of 1.4 years.

 

Below is a summary of restricted stock activity for the nine months ended September 30, 2025:

 

   Nine Months Ended September 30, 
   Shares  

Weighted Average

Grant Date Fair

Value

 
Nonvested at beginning of period   202,787   $34.72 
Granted   208,414    34.17 
Vested   (123,591)   33.90 
Forfeited   (8,110)   35.91 
Nonvested at September 30, 2025   279,500   $34.91 

 

 

Stock Options

 

A summary of the status of outstanding stock options at September 30, 2025 and changes during the nine months ended is presented below:

 

  

Nine Months Ended

September 30, 2025

     
   Options  

Weighted Average

Exercise

Price

  

Weighted Average

Remaining

Contract Life

  

Aggregate

Intrinsic

Value

 
Outstanding at beginning of period   31,013   $10.57           
Granted or assumed   -    -           
Exercised   -    -           
Forfeited   -    -           
Expired   -    -           
Outstanding at September 30, 2025   31,013   $10.57    5.1   $656,386 
                     
Exercisable at September 30, 2025   31,013   $10.57    5.1   $656,386